Market capitalization | $12.22b |
Enterprise Value | $25.00b |
P/E (TTM) P/E ratio | 21.36 |
EV/FCF (TTM) EV/FCF | 16.97 |
EV/Sales (TTM) EV/Sales | 1.19 |
P/S ratio (TTM) P/S ratio | 0.58 |
P/B ratio (TTM) P/B ratio | 0.82 |
Dividend yield | 3.09% |
Last dividend (FY24) | $0.64 |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
19 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:
19 Analysts have issued a Fresenius Medical Care AG & Co. KGaA Sponsored ADR forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 539 539 |
24%
24%
|
|
Depreciation and Amortization | 1,744 1,744 |
4%
4%
|
|
Stock Compensation | - - |
-
|
|
Operating Cash Flow | 2,842 2,842 |
25%
25%
|
|
Investments | 769 769 |
5%
5%
|
|
Dividend Paid | 355 355 |
15%
15%
|
|
Free Cash Flow | 2,102 2,102 |
39%
39%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Head office | Germany |
CEO | Helen Giza |
Employees | 119,845 |
Founded | 1996 |
Website | www.freseniusmedicalcare.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.